From the Department of Thoracic Surgery, West China Hospital, Sichuan University, Chengdu 610041, China.
Saudi Med J. 2024 May;45(5):481-489. doi: 10.15537/smj.2024.45.5.20230908.
To assess the clinical relevance and prognostic value of changes in the Naples prognostic score (NPS) after neoadjuvant chemoradiotherapy (NACR) among esophageal squamous cell carcinoma (ESCC) patients.
We studied 232 locally advanced ESCC patients who received NACR before undergoing esophagectomy retrospectively. Categorizing individuals into the elevated NPS group and the non-elevated NPS group based on the change in NPS after NACR (ΔNPS > 0 or ∆NPS ≤ 0), we examined and compared the clinicopathological characteristics, survival rates, and postoperative complications between these 2 groups (∆NPS = post-NACR NPS - pre-NACR NPS).
Results: Out of the 232 patients enrolled, 105 exhibited elevated NPS levels, while 127 showed non-elevated NPS levels. Survival analyses indicated inferior overall survival (OS) (=0.024) and recurrence-free survival (RFS) (=0.047) in the elevated NPS cohort compared to the non-elevated NPS cohort. Subsequent cox regression analyses identified the post-NACR change in NPS as an independent prognostic indicator for RFS (=0.029) and OS (=0.036).
Elevated NPS post-NACR emerged as a significant indicator of worse prognosis for locally advanced ESCC patients who underwent NACR. This finding has great potential to be useful for recognizing high-risk ESCC patients who received NACR before undergoing esophagectomy and making individualized subsequent therapeutic decisions in clinical practice.
评估新辅助放化疗(NACR)后那不勒斯预后评分(NPS)变化对食管鳞癌(ESCC)患者的临床相关性和预后价值。
我们回顾性研究了 232 例接受 NACR 后行食管切除术的局部晚期 ESCC 患者。根据 NACR 后 NPS 的变化(ΔNPS>0 或 ΔNPS≤0),将个体分为升高 NPS 组和非升高 NPS 组,比较两组的临床病理特征、生存率和术后并发症。(ΔNPS= post-NACR NPS-pre-NACR NPS)。
结果:232 例患者中,105 例 NPS 水平升高,127 例 NPS 水平非升高。生存分析显示,升高 NPS 组的总生存(OS)(=0.024)和无复发生存(RFS)(=0.047)均低于非升高 NPS 组。随后的 Cox 回归分析显示,NACR 后 NPS 的变化是 RFS(=0.029)和 OS(=0.036)的独立预后指标。
NACR 后升高的 NPS 是接受 NACR 治疗的局部晚期 ESCC 患者预后不良的重要指标。这一发现有可能用于识别接受 NACR 前接受手术治疗的高危 ESCC 患者,并在临床实践中做出个体化的后续治疗决策。